State Street Corp Talaris Therapeutics, Inc. Transaction History

State Street Corp

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$1.78 - $3.2 $514,920 - $925,699	-289,281 Reduced 81.55%	65,448 $198,000
Q1 2023 May 15, 2023	BUY	$1.09 - $2.09 $19,714 - $37,801	18,087 Added 5.37%	354,729 $666,000
Q4 2022 Feb 14, 2023	BUY	$0.94 - $1.64 $5,180 - $9,038	5,511 Added 1.66%	336,642 $343,000
Q3 2022 Nov 15, 2022	BUY	$2.3 - $5.03 $5,372 - $11,750	2,336 Added 0.71%	331,131 $871,000
Q2 2022 Aug 15, 2022	BUY	$4.51 - $9.85 $303,658 - $663,200	67,330 Added 25.75%	328,795 $1.48 Million
Q1 2022 May 16, 2022	BUY	$6.89 - $16.56 $519,940 - $1.25 Million	75,463 Added 40.57%	261,465 $2.57 Million
Q4 2021 Feb 14, 2022	BUY	$12.18 - $17.0 $693,346 - $967,725	56,925 Added 44.1%	186,002 $2.84 Million
Q3 2021 Nov 15, 2021	BUY	$11.61 - $15.99 $396,075 - $545,498	34,115 Added 35.92%	129,077 $1.75 Million
Q2 2021 Aug 16, 2021	BUY	$12.25 - $18.61 $1.16 Million - $1.77 Million	94,962 New	94,962 $1.4 Million

75.7K

Ticker TALS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,995,900
Market Cap $109M
Description
Talaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe non-malignant blood, immune, an...

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

Stay updated on State Street Corp with notifications on news.